BioSpace News Archive

The company is dropping its GLP-1 receptor agonist candidate lotiglipron after it induced elevations in liver enzymes in patients treated with the investigational drug.

A year after treatment, Vertex’s VX-880 has eliminated the need for insulin injections in two Type 1 diabetes patients in a Phase I/II clinical trial of its investigational stem cell-based therapy.

FibroGen takes another hit as its antibody hopeful fails in a second indication. The biopharma says that it is cutting costs to extend its cash runway.

New Phase II data, published in the New England Journal of Medicine, showed Lilly’s oral GLP-1 receptor agonist orforglipron induced nearly 15% weight loss in obese and overweight adults.

The acquisition of the privately-held company will bring its novel, investigational beta-lactamase inhibitors and other antimicrobials into the Japanese pharma’s pipeline.

CANbridge Pharmaceuticals, Inc. announced positive preliminary results from the ongoing Phase 1b study of omoprubart, a novel, long-acting, anti-C5 complement recombinant humanized monoclonal antibody, in paroxysmal nocturnal hemoglobinuria in China.

May Health announced new clinical trial results providing preliminary data supporting the safety and effectiveness of its Ovarian Rebalancing™ treatment for inducing ovulation in women with PCOS-related infertility.

Biora Therapeutics, Inc. shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist delivered through the BioJet™ Oral Biotherapeutic Delivery Platform in a Porcine Model,” which were presented during the American Diabetes Association 83rd Scientific Sessions, held June 23–26, 2023 in San Diego, California.

Reviva Pharmaceuticals Holdings, Inc. announced that the Company will be added to the Russell Microcap® Index, effective after the United States market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution.

PacBio announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio’s outstanding 1.50% Convertible Senior Notes due 2028, pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 in exchange for $441 million principal amount of the 2028 Notes, in a transaction exempt from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.